NCT07046052 PENG Block: Continuous Infusion vs. Programmed Intermittent Bolus in Neck of Femur Fracture
| NCT ID | NCT07046052 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University College Cork |
| Condition | Hip Fracture |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-03-28 |
| Primary Completion | 2026-01-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-03-28 with a primary completion date of 2026-01-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pericapsular Nerve Group Block (PENG) is an effective regional anaesthesia modality in providing analgesia following neck of femur fracture. Continuous PENG techniques, using indwelling catheters and infusions of local anaesthetic, facilitate the continuation of analgesia for a number of days following hip fracture surgery. It is unclear from the published literature whether an optimal strategy of local anaesthetic delivery has been characterized. Similar doses of local anaesthetic agents can be administered by either continuous infusion or timed intermittent bolus. It is unclear whether one dosing strategy is superior to the other in the context of hip fracture analgesia. The study aims to evaluate the clinical efficacy of both dosing strategies in patients undergoing hip fracture surgery.
Eligibility Criteria
Inclusion Criteria: * English-speaking * over the age of 18 years * hemiarthroplasty for fractured neck of femur * able to provide written consent. Exclusion Criteria: * under 50kg body weight. * unable to provide consent due to incapacity * pregnant women * vulnerable adults under state guardianship * Patients with pre-existing chronic pain disorders or with a history of long-term opioid use * those with contraindications to a peripheral nerve block such as local site infection, allergy to local anaesthetic or those who are coagulopathic
Contact & Investigator
Benjamin P Atterton, MBChB FRCA
STUDY DIRECTOR
Cork University Hospital & University College Cork
Frequently Asked Questions
Who can join the NCT07046052 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hip Fracture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07046052 currently recruiting?
Yes, NCT07046052 is actively recruiting participants. Contact the research team at briodnl@gmail.com for enrollment information.
Where is the NCT07046052 trial being conducted?
This trial is being conducted at Cork, Ireland.
Who is sponsoring the NCT07046052 clinical trial?
NCT07046052 is sponsored by University College Cork. The principal investigator is Benjamin P Atterton, MBChB FRCA at Cork University Hospital & University College Cork. The trial plans to enroll 150 participants.